合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）(Synthetic Haemophilus Influenzae Type b Conjugate Vaccine ( Changchun Heber Biological Technology))

概要

基本信息

药物类型

预防性疫苗、结合疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染神经系统疾病耳鼻咽喉疾病+ [3]

在研适应症

关节炎蜂窝织炎会厌炎+ [3]

非在研适应症-

原研机构

长春海伯尔生物技术有限责任公司

在研机构

长春海伯尔生物技术有限责任公司

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

关联

2

项与合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）相关的临床试验

CTR20210935 / Recruiting临床3期

合成b型流感嗜血杆菌结合疫苗III期临床研究

评价长春海伯尔生物技术有限责任公司生产的合成b型流感嗜血杆菌结合疫苗在2月龄～5周岁健康婴幼儿中的免疫原性和安全性

开始日期2021-05-15

申办/合作机构

长春海伯尔生物技术有限责任公司

CTR20192500 / Active, not recruiting临床1期

合成b型流感嗜血杆菌结合疫苗I期临床研究

初步考察长春海伯尔生物技术有限责任公司生产的合成b型流感嗜血杆菌结合疫苗在健康受试者中的安全性

开始日期2020-06-20

申办/合作机构

长春海伯尔生物技术有限责任公司

100 项与合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）相关的临床结果

登录后查看更多信息

100 项与合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）相关的转化医学

登录后查看更多信息

100 项与合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）相关的专利（医药）

登录后查看更多信息

5

项与合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）相关的文献（医药）

2019-03-01·Vaccine3区 · 医学

Impact of the introduction of the Haemophilus influenzae type b conjugate vaccine in an urban setting in southern India

3区 · 医学

Article

作者: Santosham, Mathuram ; Nedunchelian, Krishnamoorthy ; Suresh, Saradha ; Fitzwater, Sean Patrick ; Ramachandran, Padmanabhan ; Chandran, Aruna ; Kahn, Geoffrey D

INTRODUCTIONHaemophilus influenzae type b was the leading cause of bacterial meningitis in infants and children below the age of two years prior to the introduction of H. influenzae type b conjugate vaccines. In December 2011, the Indian government introduced H. influenzae b vaccine in the state of Tamilnadu. A prospective surveillance for bacterial meningitis was established at the Institute of Child Health in Chennai to evaluate the etiology of meningitis and impact of the vaccine.MATERIAL AND METHODSInfants aged one to 23 months who were admitted to the hospital with symptoms of suspected bacterial meningitis were enrolled and lumbar puncture was performed. Cerebrospinal fluid samples were analyzed for white blood cells, protein, and glucose. Bacterial culture and a latex agglutination test for common bacterial pathogens were performed.RESULTSBetween January 2009 and March 2014, 4,770 children with suspected bacterial meningitis were enrolled. Prior to the introduction of the vaccine, an average of 11.7 cases of H. influenzae b meningitis and 31.1 cases of probable meningitis with no etiology were identified each year. After introduction, the number of cases were reduced by 79% and 44% respectively. The average H. influenzae b vaccine coverage after introduction was 69% among all children with clinically suspected meningitis. In contrast, the mean number of aseptic meningitis and pneumococcal meningitis cases remained stable throughout the pre and post vaccination period; 28.2 and 4.8 per year, respectively.CONCLUSIONSH. influenzae b conjugate vaccine reduced the number of cases of H. influenzae b meningitis and probable meningitis within the first two years of its introduction. The impact against meningitis was higher than the vaccination rate, indicating indirect effects of the vaccine. India has recently scaled up the use of Hib conjugate vaccine throughout the country which should substantially reduce childhood meningitis rates further in the country.

2009-01-01·Pediatric Infectious Disease Journal4区 · 医学

Nontypeable Haemophilus influenzae as a Pathogen in Children

4区 · 医学

Review

作者: Stephen I. Pelton ; Arne Forsgren ; Jennelle M. Kyd ; Timothy F. Murphy ; Howard Faden ; Lauren O. Bakaletz ; Jose Campos ; Mumtaz Virji

Nontypeable Haemophilus influenzae is a significant pathogen in children, causing otitis media, sinusitis, conjunctivitis, pneumonia, and occasionally invasive infections. H. influenzae type b conjugate vaccines have no effect on infections caused by nontypeable strains because nontypeable strains are nonencapsulated. Approximately, one-third of episodes of otitis media are caused by nontypeable H. influenzae and the bacterium is the most common cause of recurrent otitis media. Recent progress in elucidating molecular mechanisms of pathogenesis, understanding the role of biofilms in otitis media and an increasing understanding of immune responses have potential for development of novel strategies to improve prevention and treatment of otitis media caused by nontypeable H. influenzae. Feasibility of vaccination for prevention of otitis media due to nontypeable H. influenzae was recently demonstrated in a clinical trial with a vaccine that included the surface virulence factor, protein D.

1997-10-02·New England Journal of Medicine1区 · 医学

Bacterial Meningitis in the United States in 1995

1区 · 医学

Article

作者: Lefkowitz, L ; Robinson, K ; Schuchat, A ; Harrison, L H ; Perkins, B A ; Wenger, J D ; Reingold, A L ; Farley, M

BACKGROUNDBefore the introduction of the conjugate vaccines, Haemophilus influenzae type b was the major cause of bacterial meningitis in the United States, and meningitis was primarily a disease of infants and young children. We describe the epidemiologic features of bacterial meningitis five years after the H. influenzae type b conjugate vaccines were licensed for routine immunization of infants.METHODSData were collected from active, population-based surveillance for culture-confirmed meningitis and other invasive bacterial disease during 1995 in laboratories serving all the acute care hospitals in 22 counties of four states (total population, more than 10 million). The rates were compared with those for 1986 obtained by similar surveillance.RESULTSOn the basis of 248 cases of bacterial meningitis in the surveillance areas, the rates of meningitis (per 100,000) for the major pathogens in 1995 were Streptococcus pneumoniae, 1.1; Neisseria meningitidis, 0.6; group B streptococcus, 0.3; Listeria monocytogenes, 0.2; and H. influenzae, 0.2. Group B streptococcus was the predominant pathogen among newborns, N. meningitidis among children 2 to 18 years old, and S. pneumoniae among adults. Pneumococcal meningitis had the highest case fatality rate (21 percent) and in 36 percent of cases was caused by organisms that were not susceptible to penicillin. From these data, we estimate that 5755 cases of bacterial meningitis were caused by these five pathogens in the United States in 1995, as compared with 12,920 cases in 1986, a reduction of 55 percent. The median age of persons with bacterial meningitis increased greatly, from 15 months in 1986 to 25 years in 1995, largely as a result of a 94 percent reduction in the number of cases of H. influenzae meningitis.CONCLUSIONSBecause of the vaccine-related decline in meningitis due to H. influenzae type b, bacterial meningitis in the United States is now a disease predominantly of adults rather than of infants and young children.

100 项与合成b型流感嗜血杆菌结合疫苗（长春海伯尔生物）相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
关节炎	临床3期	中国	长春海伯尔生物技术有限责任公司	2021-05-15
蜂窝织炎	临床3期	中国	长春海伯尔生物技术有限责任公司	2021-05-15
会厌炎	临床3期	中国	长春海伯尔生物技术有限责任公司	2021-05-15
嗜血杆菌感染	临床3期	中国	长春海伯尔生物技术有限责任公司	2021-05-15
脑膜炎	临床3期	中国	长春海伯尔生物技术有限责任公司	2021-05-15
肺炎	临床3期	中国	长春海伯尔生物技术有限责任公司	2021-05-15